DK1513835T3 - Piperazinylacylpiperidinderivater, fremstilling og terapeutisk anvendelse heraf - Google Patents

Piperazinylacylpiperidinderivater, fremstilling og terapeutisk anvendelse heraf

Info

Publication number
DK1513835T3
DK1513835T3 DK03757108T DK03757108T DK1513835T3 DK 1513835 T3 DK1513835 T3 DK 1513835T3 DK 03757108 T DK03757108 T DK 03757108T DK 03757108 T DK03757108 T DK 03757108T DK 1513835 T3 DK1513835 T3 DK 1513835T3
Authority
DK
Denmark
Prior art keywords
preparation
therapeutic use
piperazinylacylpiperidine
derivatives
piperazinylacylpiperidine derivatives
Prior art date
Application number
DK03757108T
Other languages
Danish (da)
English (en)
Inventor
Michael Bosch
Santos Victor Dos
Jean Marc Herbert
Dino Nisato
Bernard Tonnerre
Jean Wagnon
Francoise Bono
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Application granted granted Critical
Publication of DK1513835T3 publication Critical patent/DK1513835T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DK03757108T 2002-06-07 2003-06-05 Piperazinylacylpiperidinderivater, fremstilling og terapeutisk anvendelse heraf DK1513835T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0207001 2002-06-07

Publications (1)

Publication Number Publication Date
DK1513835T3 true DK1513835T3 (da) 2006-12-27

Family

ID=29724874

Family Applications (2)

Application Number Title Priority Date Filing Date
DK03757108T DK1513835T3 (da) 2002-06-07 2003-06-05 Piperazinylacylpiperidinderivater, fremstilling og terapeutisk anvendelse heraf
DK03757109T DK1513836T3 (da) 2002-06-07 2003-06-05 Piperazinylacylpiperidinderivater, fremstilling og terapeutisk anvendelse heraf

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK03757109T DK1513836T3 (da) 2002-06-07 2003-06-05 Piperazinylacylpiperidinderivater, fremstilling og terapeutisk anvendelse heraf

Country Status (29)

Country Link
US (2) US7468368B2 (enExample)
EP (2) EP1513836B1 (enExample)
JP (2) JP4437075B2 (enExample)
KR (1) KR100970812B1 (enExample)
CN (1) CN100448875C (enExample)
AR (2) AR040246A1 (enExample)
AT (2) ATE336491T1 (enExample)
AU (2) AU2003255644B2 (enExample)
BR (1) BR0311828A (enExample)
CA (1) CA2487840C (enExample)
CY (2) CY1107330T1 (enExample)
DE (2) DE60305037T2 (enExample)
DK (2) DK1513835T3 (enExample)
EA (1) EA007501B1 (enExample)
ES (2) ES2264001T3 (enExample)
HR (1) HRP20041157B1 (enExample)
IS (1) IS2302B (enExample)
MA (1) MA27233A1 (enExample)
ME (1) MEP11508A (enExample)
MX (1) MXPA04012341A (enExample)
NO (1) NO329669B1 (enExample)
NZ (1) NZ537044A (enExample)
PL (1) PL208711B1 (enExample)
PT (2) PT1513835E (enExample)
RS (2) RS20050014A (enExample)
TW (2) TWI319400B (enExample)
UA (1) UA77526C2 (enExample)
WO (2) WO2003104225A1 (enExample)
ZA (1) ZA200409823B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2862968B1 (fr) * 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique
FR2862967B1 (fr) * 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique
WO2005068445A2 (en) * 2004-01-08 2005-07-28 Syngenta Participations Ag Pesticidal heterocyclic dihaloallyl compounds
CA2572821A1 (en) * 2004-07-16 2006-01-26 Janssen Pharmaceutica N.V. Dimeric compounds of piperidine, piperazine or morpholine or their 7-membered analogs suitable for the treatment of neurodegenerative disorders
EP2289510A1 (en) * 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
EP2594318B1 (en) * 2005-04-15 2020-06-10 University Of North Carolina At Chapel Hill Methods of facilitating cell survival using neurotrophin mimetics
AU2008227100B2 (en) * 2007-03-15 2014-01-09 Albany Molecular Research, Inc. Pyridazinone derivatives useful as glucan synthase inhibitors
WO2008144764A1 (en) * 2007-05-21 2008-11-27 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
FR2932482B1 (fr) * 2008-06-13 2010-10-08 Sanofi Aventis Nouveaux derives de (phenyl-3,6-dihydro-2h-pyridinyl)- (piperazinyl ponte)-1-alcanone et leur utilisation comme inhibiteurs de p75
FR2932481B1 (fr) * 2008-06-13 2010-10-08 Sanofi Aventis Derives de 4-{2-°4-phenyl-3,6-dihydro-2h-pyridin-1-yl!-2- oxo-alkyl}-1-piperazin-2-one, leur preparation et leur application en therapeutique.
WO2011060262A1 (en) 2009-11-12 2011-05-19 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
FR2953839A1 (fr) 2009-12-14 2011-06-17 Sanofi Aventis Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75
SG181570A1 (en) 2009-12-14 2012-07-30 Merck Patent Gmbh Inhibitors of sphingosine kinase
FR2953836B1 (fr) * 2009-12-14 2012-03-16 Sanofi Aventis Nouveaux derives (heterocycle-tetrahydro-pyridine)-(piperazinyl)-1-alcanone et (heterocycle-dihydro-pyrrolidine)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75
EP2606894A1 (en) 2011-12-20 2013-06-26 Sanofi Novel therapeutic use of p75 receptor antagonists
AU2018334290A1 (en) 2017-09-18 2020-04-02 Goldfinch Bio, Inc. Pyridazinones and methods of use thereof
KR20250171415A (ko) 2018-09-18 2025-12-08 쥐에프비(에이비씨), 엘엘씨 피리다지논 및 이의 사용 방법
EP3858439A1 (en) * 2020-02-03 2021-08-04 Esteve Pharmaceuticals, S.A. Amide derivatives having multimodal activity against pain

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX173180B (es) * 1987-10-26 1994-02-07 Pfizer Procedimiento para preparar agentes ansioliticos
FR2747041B1 (fr) * 1996-04-05 1998-05-22 Cird Galderma Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies
US6468990B1 (en) * 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor
FR2803593B1 (fr) 2000-01-06 2002-02-15 Sanofi Synthelabo Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant

Also Published As

Publication number Publication date
AU2003255644A1 (en) 2003-12-22
EP1513835A1 (fr) 2005-03-16
EP1513836A1 (fr) 2005-03-16
AR040246A1 (es) 2005-03-23
JP2005534661A (ja) 2005-11-17
RS52588B (sr) 2013-04-30
NO329669B1 (no) 2010-11-29
ZA200409823B (en) 2006-07-26
DE60307632D1 (de) 2006-09-28
EA200401470A1 (ru) 2005-06-30
ATE325122T1 (de) 2006-06-15
CY1105784T1 (el) 2011-02-02
PT1513835E (pt) 2006-12-29
NZ537044A (en) 2006-08-31
CY1107330T1 (el) 2012-11-21
EP1513835B1 (fr) 2006-08-16
JP4437075B2 (ja) 2010-03-24
ES2264001T3 (es) 2006-12-16
MXPA04012341A (es) 2005-09-30
TW200407321A (en) 2004-05-16
KR100970812B1 (ko) 2010-07-16
CA2487840C (en) 2011-05-17
US20060167007A1 (en) 2006-07-27
UA77526C2 (en) 2006-12-15
NO20045331L (no) 2005-03-07
WO2003104225A1 (fr) 2003-12-18
DK1513836T3 (da) 2006-09-11
US7294628B2 (en) 2007-11-13
MA27233A1 (fr) 2005-02-01
TWI319400B (en) 2010-01-11
CN1675203A (zh) 2005-09-28
DE60305037T2 (de) 2006-12-14
JP2005533051A (ja) 2005-11-04
CA2487840A1 (en) 2003-12-18
US7468368B2 (en) 2008-12-23
JP4441401B2 (ja) 2010-03-31
US20050176722A1 (en) 2005-08-11
TW200400185A (en) 2004-01-01
AR040247A1 (es) 2005-03-23
HRP20041157B1 (en) 2012-11-30
HK1076110A1 (zh) 2006-01-06
BR0311828A (pt) 2005-03-29
WO2003104226A1 (fr) 2003-12-18
HRP20041157A2 (en) 2005-06-30
ES2271637T3 (es) 2007-04-16
IS2302B (is) 2007-10-15
CN100448875C (zh) 2009-01-07
KR20050008802A (ko) 2005-01-21
DE60305037D1 (de) 2006-06-08
RS20050014A (sr) 2007-06-04
IS7579A (is) 2004-12-02
EP1513836B1 (fr) 2006-05-03
PT1513836E (pt) 2006-09-29
AU2003255645A1 (en) 2003-12-22
EA007501B1 (ru) 2006-10-27
AU2003255644B2 (en) 2009-02-05
PL208711B1 (pl) 2011-05-31
MEP11508A (en) 2010-06-10
ATE336491T1 (de) 2006-09-15
PL374729A1 (en) 2005-10-31
DE60307632T2 (de) 2007-08-09
TWI283671B (en) 2007-07-11

Similar Documents

Publication Publication Date Title
IS2485B (is) Fenýlsúlfónýl-1,3-díhýdró-2H-indól-2-ón afleiður,framleiðsla þeirra og notkun í meðferðarskyni
NO20052855D0 (no) Fosfonoksykinazolinderivater og farmasoytisk anvendelse derav.
IS6661A (is) Bensimídasólafleiður, framleiðsla þeirra og meðferðarleg notkun
DK1513836T3 (da) Piperazinylacylpiperidinderivater, fremstilling og terapeutisk anvendelse heraf
DK1537096T3 (da) Derivater af dioxan-2-alkylcarbamater, fremstilling og terapeutisk anvendelse heraf
DK1590321T3 (da) Arylalkylcarbamat-derivater, fremstilling og terapeutisk anvendelse deraf
DK1161434T3 (da) Pyridopyranoazepinderivater, deres fremstilling og terapeutiske anvendelse
DK1417189T3 (da) Acylaminothiazolderivater, fremstilling og terapeutisk anvendelse heraf
DK1525193T3 (da) Acylaminothiazolderivater, deres fremstilling og deres terapeutiske anvendelse
DK1556382T3 (da) 3-Phenylpyridoindolderivater, fremstilling og terapeutisk anvendelse deraf
DK1387838T3 (da) Cyanoanthranylamid-derivater og deres anvendelse som lægemidler
NO20033120L (no) 2-arylimino-2,3-dihydrotiazolderivater, fremgangsmåter for fremstilling derav og terapeutisk anvendelse derav
DK1773829T3 (da) Aminotropanderivater, fremstilling og terapeutiske anvendelser heraf
IS2487B (is) Asýloxýpýrrólidín afleiður, framleiðsla og meðferðarnotkun þar á
NO20053805D0 (no) Diarylmetylindenpiperidinderivater, framgangsmate for fremstilling derav, og anvendelse derav
DK1742947T3 (da) 6-substituerede pyridoindolanderivater, fremstilling og terapeutisk anvendelse heraf
NO20044090L (no) Substituert 3-fenyl-5-alkoksy-1,3,4-oksadiazol-24neJr, fremstilling derav og anvendelse i medikamenter
IS6391A (is) 2-Arýlkínólín afleiður, framleiðsla og meðferðarleg notkun á þeim
SI1513836T1 (sl) Derivati piperazinilacilpiperidina, njihova priprava in njihova terapevtska uporaba
SI1513835T1 (sl) Derivati piperazunilacilpiperidina, njihova priprava in njihova terapevtska uporaba
DK1309594T3 (da) Benzimidazolderivater, fremstilling heraf og terapeutisk anvendelse heraf
SI1525198T1 (sl) Derivati aciloksi pirolidina in njihova uporaba kot ligandi receptorjev V1b ali V1b in V1a od AVP
SI1525193T1 (sl) Acilaminotiazolni derivati in njihova uporaba kotinhibitorji beta-amiloida